000127660 001__ 127660
000127660 005__ 20240228140942.0
000127660 0247_ $$2doi$$a10.1007/s00066-015-0825-3
000127660 0247_ $$2pmid$$apmid:25737378
000127660 0247_ $$2ISSN$$a0039-2073
000127660 0247_ $$2ISSN$$a0179-7158
000127660 0247_ $$2ISSN$$a1439-099X
000127660 037__ $$aDKFZ-2017-03683
000127660 041__ $$aeng
000127660 082__ $$a610
000127660 1001_ $$aUhl, Matthias$$b0
000127660 245__ $$aCarbon ion beam treatment in patients with primary and recurrent sacrococcygeal chordoma.
000127660 260__ $$aHeidelberg$$bSpringer51814$$c2015
000127660 264_1 $$2Crossref$$3online$$bSpringer Science and Business Media LLC$$c2015-03-04
000127660 264_1 $$2Crossref$$3print$$bSpringer Science and Business Media LLC$$c2015-07-01
000127660 264_1 $$2Crossref$$3print$$bSpringer Science and Business Media LLC$$c2015-07-01
000127660 3367_ $$2DRIVER$$aarticle
000127660 3367_ $$2DataCite$$aOutput Types/Journal article
000127660 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524140042_24121
000127660 3367_ $$2BibTeX$$aARTICLE
000127660 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127660 3367_ $$00$$2EndNote$$aJournal Article
000127660 520__ $$aThe purpose of this work was to evaluate the results of high-dose radiation treatment using carbon ion therapy, alone or combined with intensity-modulated radiation treatment (IMRT), in patients with sacral chordoma.Between 2009 and 2012, 56 patients with sacral chordoma were treated in our center. The tumor was located above S3 in 33 patients and in S3 or below in 23 patients. In all, 41 patients received radiation therapy for the primary tumor, while 15 patients were treated for the recurrent tumor. Toxicity was measured using NCI CTCAE v.4.03. Local control (LC) and overall survival (OS) were evaluated with the Kaplan-Meier method.A total of 23 patients were irradiated with carbon ions in combination with photon IMRT, while 33 received carbon ion therapy only. Forty-three patients had a macroscopic tumor at treatment start with a median tumor size (GTV) of 244 ml (range 5-1188 ml). The median total dose was 66 Gy (range 60-74 Gy; RBE). After a median follow-up time of 25 months, the 2- and 3-year local control probability was 76 % and 53 %, respectively. The overall survival rate was 100 %. Treatment for primary tumor and male patients resulted in significant better local control. No higher toxicity occurred within the follow-up time.High-dose photon/carbon ion beam radiation therapy is safe and, especially for primary sacral chordomas, highly effective. A randomized trial is required to evaluate the role of primary definitive hypofractionated particle therapy compared with surgery with or without adjuvant radiotherapy.
000127660 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000127660 542__ $$2Crossref$$i2015-03-04$$uhttp://www.springer.com/tdm
000127660 588__ $$aDataset connected to CrossRef, PubMed,
000127660 7001_ $$aWelzel, Thomas$$b1
000127660 7001_ $$aJensen, Alexandra$$b2
000127660 7001_ $$aEllerbrock, Malte$$b3
000127660 7001_ $$aHaberer, Thomas$$b4
000127660 7001_ $$0P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aJäkel, Oliver$$b5$$udkfz
000127660 7001_ $$aHerfarth, Klaus$$b6
000127660 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b7$$eLast author$$udkfz
000127660 77318 $$2Crossref$$3journal-article$$a10.1007/s00066-015-0825-3$$bSpringer Science and Business Media LLC$$d2015-03-04$$n7$$p597-603$$tStrahlentherapie und Onkologie$$v191$$x0179-7158$$y2015
000127660 773__ $$0PERI:(DE-600)2003907-4$$a10.1007/s00066-015-0825-3$$gVol. 191, no. 7, p. 597 - 603$$n7$$p597-603$$tStrahlentherapie und Onkologie$$v191$$x0179-7158$$y2015
000127660 909CO $$ooai:inrepo02.dkfz.de:127660$$pVDB
000127660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000127660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000127660 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000127660 9141_ $$y2015
000127660 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127660 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127660 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTRAHLENTHER ONKOL : 2015
000127660 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127660 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127660 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127660 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127660 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127660 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000127660 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127660 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000127660 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lMedizinische Physik in der Strahlentherapie$$x0
000127660 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x1
000127660 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000127660 980__ $$ajournal
000127660 980__ $$aVDB
000127660 980__ $$aI:(DE-He78)E040-20160331
000127660 980__ $$aI:(DE-He78)E050-20160331
000127660 980__ $$aI:(DE-He78)L101-20160331
000127660 980__ $$aUNRESTRICTED
000127660 999C5 $$1JR Salisbury$$2Crossref$$9-- missing cx lookup --$$a10.1002/path.1711710112$$p59 -$$tJ Pathol$$uSalisbury JR, Deverell MH, Cookson MJ et al (1993) Three-dimensional reconstruction of human embryonic notochords: clue to the pathogenesis of chordoma. J Pathol 171:59–62$$v171$$y1993
000127660 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/cncr.28032$$uSmoll NR, Gautschi OP, Radovanovic et al (2013) Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population. Cancer 119:2029–2037
000127660 999C5 $$1KW Chen$$2Crossref$$9-- missing cx lookup --$$a10.1038/sc.2009.95$$p166 -$$tSpinal Cord$$uChen KW, Yang HL, Lu J et al (2010) Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients. Spinal Cord 48:166–171$$v48$$y2010
000127660 999C5 $$1EY Cheng$$2Crossref$$9-- missing cx lookup --$$a10.1097/00007632-199908150-00004$$p1639 -$$tSpine$$uCheng EY, Ozerdemoglu RA, Transfeldt EE et al (1999) Lumbosacral chordoma. Prognostic factors and treatment. Spine (Phila Pa 1976) 24:1639–1645$$v24$$y1999
000127660 999C5 $$1B Fuchs$$2Crossref$$9-- missing cx lookup --$$a10.2106/JBJS.D.02693$$p2211 -$$tJ Bone Joint Surg Am$$uFuchs B, Dickey ID, Yaszemski MJ et al (2005) Operative management of sacral chordoma. J Bone Joint Surg Am 87:2211–2216$$v87$$y2005
000127660 999C5 $$1S Osaka$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00432-005-0067-3$$p213 -$$tJ Cancer Res Clin Oncol$$uOsaka S, Kodoh O, Sugita H et al (2006) Clinical significance of a wide excision policy for sacrococcygeal chordoma. J Cancer Res Clin Oncol 132:213–218$$v132$$y2006
000127660 999C5 $$1B Stener$$2Crossref$$9-- missing cx lookup --$$a10.1097/00007632-197812000-00009$$p351 -$$tSpine$$uStener B, Gunterberg B (1978) High amputation of the sacrum for extirpation of tumors. Principles and technique. Spine (Phila Pa 1976) 3:351–366$$v3$$y1978
000127660 999C5 $$1C Devin$$2Crossref$$9-- missing cx lookup --$$a10.1002/jso.20477$$p203 -$$tJ Surg Oncol$$uDevin C, Chong PY, Holt GE et al (2006) Level-adjusted perioperative risk of sacral amputations. J Surg Oncol 94:203–211$$v94$$y2006
000127660 999C5 $$1PC Hsieh$$2Crossref$$9-- missing cx lookup --$$a10.1097/BRS.0b013e3181b61b90$$p2233 -$$tSpine$$uHsieh PC, Xu R, Sciubba DM et al (2009) Long-term clinical outcomes following en bloc resections for sacral chordomas and chondrosarcomas: a series of twenty consecutive patients. Spine (Phila Pa 1976) 34:2233–2239$$v34$$y2009
000127660 999C5 $$1KM Davidge$$2Crossref$$uDavidge KM, Eskicioglu C, Lipa J et al (2010) Qualitative assessment of patient experiences following sacrectomy. J Surg Oncol 101:447–450$$y2010
000127660 999C5 $$1CA Hulen$$2Crossref$$9-- missing cx lookup --$$a10.2106/JBJS.D.02533$$p1532 -$$tJ Bone Joint Surg Am$$uHulen CA, Temple HT, Fox WP et al (2006) Oncologic and functional outcome following sacrectomy for sacral chordoma. J Bone Joint Surg Am 88:1532–1539$$v88$$y2006
000127660 999C5 $$1JE York$$2Crossref$$9-- missing cx lookup --$$a10.1097/00006123-199901000-00041$$p74 -$$tNeurosurgery$$uYork JE, Kaczaraj A, Abi-Said D et al (1999) Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery 44:74–79; discussion 9–80$$v44$$y1999
000127660 999C5 $$1SU Lee$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00066-014-0604-6$$p806 -$$tStrahlenther Onkol$$uLee SU, Park JW, Kim TH et al (2014) Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol 190:806–814$$v190$$y2014
000127660 999C5 $$1Y Demizu$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00066-013-0489-9$$p186 -$$tStrahlenther Onkol$$uDemizu Y, Fujii O, Terashima K et al (2014) Particle therapy for mucosal melanoma of the head and neck. A single-institution retrospective comparison of proton and carbon ion therapy. Strahlenther Onkol 190:186–191$$v190$$y2014
000127660 999C5 $$1M Mizumoto$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00066-013-0390-6$$p656 -$$tStrahlenther Onkol$$uMizumoto M, Okumura T, Ishikawa E et al (2013) Reirradiation for recurrent malignant brain tumor with radiotherapy or proton beam therapy. Technical considerations based on experience at a single institution. Strahlenther Onkol 189:656–663$$v189$$y2013
000127660 999C5 $$1M Durante$$2Crossref$$9-- missing cx lookup --$$a10.1038/nrclinonc.2009.183$$p37 -$$tNat Rev Clin Oncol$$uDurante M, Loeffler JS (2010) Charged particles in radiation oncology. Nat Rev Clin Oncol 7:37–43$$v7$$y2010
000127660 999C5 $$1M Uhl$$2Crossref$$9-- missing cx lookup --$$a10.1002/cncr.28606$$p1579 -$$tCancer$$uUhl M, Mattke M, Welzel T et al (2014) High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results. Cancer 120:1579–1585$$v120$$y2014
000127660 999C5 $$1M Uhl$$2Crossref$$9-- missing cx lookup --$$a10.1002/cncr.28877$$p3410 -$$tCancer$$uUhl M, Mattke M, Welzel T et al (2014) Highly effective treatment of skull base chordoma with carbon ion irradiation using a raster scan technique in 155 patients: first long-term results. Cancer 120:3410–3417$$v120$$y2014
000127660 999C5 $$1M Uhl$$2Crossref$$9-- missing cx lookup --$$a10.1186/1748-717X-9-100$$p100 -$$tRadiat Oncol$$uUhl M, Edler L, Jensen AD et al (2014) Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma—the ISAC trial protocol. Radiat Oncol 9:100$$v9$$y2014
000127660 999C5 $$1D Schulz-Ertner$$2Crossref$$9-- missing cx lookup --$$a10.1002/cncr.21158$$p338 -$$tCancer$$uSchulz-Ertner D, Nikoghosyan A, Didinger B et al (2005) Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer 104:338–344$$v104$$y2005
000127660 999C5 $$1M Uhl$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00066-014-0608-2$$p686 -$$tStrahlenther Onkol$$uUhl M, Welzel T, Oelmann J et al (2014) Active raster scanning with carbon ions: reirradiation in patients with recurrent skull base chordomas and chondrosarcomas. Strahlenther Onkol 190:686–691$$v190$$y2014
000127660 999C5 $$1L Park$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ijrobp.2006.02.059$$p1514 -$$tInt J Radiat Oncol Biol Phys$$uPark L, Delaney TF, Liebsch NJ et al (2006) Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 65:1514–1521$$v65$$y2006
000127660 999C5 $$1YL Chen$$2Crossref$$9-- missing cx lookup --$$a10.1097/BRS.0b013e318296e7d7$$pE930 -$$tSpine$$uChen YL, Liebsch N, Kobayashi W et al (2013) Definitive high-dose photon/proton radiotherapy for unresected mobile spine and sacral chordomas. Spine (Phila Pa 1976) 38:E930–E936$$v38$$y2013
000127660 999C5 $$1M Mima$$2Crossref$$9-- missing cx lookup --$$a10.1259/bjr.20130512$$p20130512 -$$tBr J Radiol$$uMima M, Demizu Y, Jin D et al (2014) Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma. Br J Radiol 87:20130512$$v87$$y2014
000127660 999C5 $$1R Imai$$2Crossref$$9-- missing cx lookup --$$a10.1259/bjr/13783281$$pS48 -$$tBr J Radiol$$uImai R, Kamada T, Sugahara S et al (2011) Carbon ion radiotherapy for sacral chordoma. Br J Radiol 84:Spec No 1:S48–S54$$v84$$y2011
000127660 999C5 $$1TF DeLaney$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ijrobp.2008.08.058$$p732 -$$tInt J Radiat Oncol Biol Phys$$uDeLaney TF, Liebsch NJ, Pedlow FX et al (2009) Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 74:732–739$$v74$$y2009
000127660 999C5 $$1T Yanagi$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.radonc.2009.08.041$$p60 -$$tRadiother Oncol$$uYanagi T, Kamada T, Tsuji H et al (2010) Dose-volume histogram and dose-surface histogram analysis for skin reactions to carbon ion radiotherapy for bone and soft tissue sarcoma. Radiother Oncol 95:60–65$$v95$$y2010
000127660 999C5 $$1A Staab$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ijrobp.2011.02.018$$pe489 -$$tInt J Radiat Oncol Biol Phys$$uStaab A, Rutz HP, Ares C et al (2011) Spot-scanning-based proton therapy for extracranial chordoma. Int J Radiat Oncol Biol Phys 81:e489–e496$$v81$$y2011
000127660 999C5 $$1A Zabel-du Bois$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.radonc.2010.10.008$$p408 -$$tRadiother Oncol$$uZabel-du Bois A, Nikoghosyan A, Schwahofer A et al (2010) Intensity modulated radiotherapy in the management of sacral chordoma in primary versus recurrent disease. Radiother Oncol 97:408–412$$v97$$y2010